µ¿¾çÀÎÀÇ ÆíµÎÅë Æ¯Â¡ ¿¬±¸
ÁÖ¿ä Áø·á ºÐ¾ß´Â ³úÁ¹Áß, ³ú°æ»ö, µÎÅëÀÌ¸ç °í´ë ±¸·Îº´¿ø ³ú½Å°æ¼¾ÅÍ¿¡¼ µÎÅë Ŭ¸®´ÐÀ» ¿î¿µÇϰí ÀÖ´Ù.
ÆíµÎÅëÀÇ ´Ù¾çÇÑ Áõ»ó Áß ¼¾çÀΰú´Â ´Ù¸¥ µ¿¾çÀθ¸ÀÇ Æ¯Â¡À» ã°í ÀÖÀ¸¸ç, ÆíµÎÅë ±Þ¼º±â Ä¡·á¿Í »îÀÇ Áú °³¼±À» À§ÇÑ ¿¹¹æÄ¡·á ¹× ¸¸¼ºÈ ¹æÁö¸¦ À§ÇÑ ¸ÞÄ¿´ÏÁòÀ» ¿¬±¸Çϰí ÀÖ´Ù. ¶ÇÇÑ, ÆíµÎÅë Ä¡·á¾à¹°¿¡ ´ëÇÑ ¿©·¯ ±¹Á¦ ÀÓ»ó½ÃÇè¿¡ Âü¿©Çϰí ÀÖ´Ù.
| Á¦ ¸ñ | Impact of in-hospital COVID-19 quarantine policy changes on quality of acute stroke care: a single center experience | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2025. 01 | ¹ßÇ¥Áö | Frontiers in Neurology |
| Á¦ ¸ñ | Long-Chain Polysaturated Fatty Acid in Atrial Fibrillation-Associated Stroke: Lipidomic-GWAS Study | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024. 12 | ¹ßÇ¥Áö | Thrombosis and Haemostasis |
| Á¦ ¸ñ | Perfusion Imaging-Based Triage for Acute Ischemic Stroke: Trends in Use and Impact on Clinical Outcomes | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024. 09 | ¹ßÇ¥Áö | Stroke: Vascular and Interventional Neurology |
| Á¦ ¸ñ | Sarcopenia is a predictor for Alzheimer¡¯s continuum and related clinical outcomes | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024. 09 | ¹ßÇ¥Áö | Scientific Reports |
| Á¦ ¸ñ | High glycated albumin is associated with early neurological deterioration in patients with acute ischemic stroke | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024. 08 | ¹ßÇ¥Áö | BMC Neurology |
| Á¦ ¸ñ | Ethnic differences in the effects of apolipoprotein E ɛ4 and vascular risk factors on accelerated brain aging | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024. 07 | ¹ßÇ¥Áö | Brain Communications |
| Á¦ ¸ñ | Predicting cerebrovascular age and its clinical relevance: Modeling using 3D morphological features of brain vessels | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024. 06 | ¹ßÇ¥Áö | Heliyon |
ÆíµÎÅë / ÆíµÎÅë ±Þ¼º±â Ä¡·á¿Í »îÀÇ Áú °³¼±À» À§ÇÑ ¿¹¹æÄ¡·á ¹× ¸¸¼ºÈ ¹æÁö¸¦ À§ÇÑ ¸ÞÄ¿´ÏÁòÀ» ¿¬±¸Çϰí ÀÖ´Ù. ¶ÇÇÑ, ÆíµÎÅë Ä¡·á¾à¹°¿¡ ´ëÇÑ ¿©·¯ ±¹Á¦ ÀÓ»ó½ÃÇè¿¡ Âü¿©Çϰí ÀÖ´Ù.
ȯÀÚÀÇ »îÀÇ Áú °³¼±
ÁúȯÀ» ÀÌÇØÇÏ°í Æ÷±âÇÏÁö ¾Ê°í ÀÇ»ç¿Í ÇÔ²² Ä¡·á¿¡ Âü¿©ÇÏ¸é ¹Ýµå½Ã ´õ ³ªÀº »îÀ» »ì ¼ö ÀÖ½À´Ï´Ù.

°í·Á´ëÇб³ ±¸·Îº´¿øÀº 1983³â ÀÇ·á ¼Ò¿Ü Áö¿ªÀÇ ÀÇ·á º¹Áö¸¦ ½ÇÇöÇϰڴٴ ¸ñÇ¥·Î ¼³¸³µÈ ÀÌÈÄ ´ëÇк´¿øÀÇ »ç¸íÀ» ´ÙÇϸç Áø·á, ±³À°, ¿¬±¸ 3´ë ÇÙ½É ºÐ¾ß¿¡¼ ºñ¾àÀûÀ¸·Î ¹ßÀüÇß½À´Ï´Ù. ±Ç¿ª ³» ÃÖ»óÀ§ ÀÇ·á±â°üÀ¸·Î¼ ÁßÁõȯÀÚ Äɾ À§ÇÑ Àü¹æÀ§ ½Ã½ºÅÛÀ» °®Ãß°í ÀÖÀ¸¸ç ƯÈ÷ ¾Ïº´¿ø, ±Ç¿ªÀÀ±ÞÀÇ·á¼¾ÅÍ, Àü±¹ À¯ÀÏÀÇ ÁßÁõ¿Ü»óÀü¹®ÀǼö·Ã¼¾ÅÍ, º¸°Çº¹ÁöºÎ ÁöÁ¤ °íÀ§Çè»ê¸ð¡¤½Å»ý¾ÆÅëÇÕÄ¡·á¼¾ÅÍ, ¼¿ï ¼ºÎ±Ç¿ª À¯ÀÏ Áö¿ªÀǾàǰ
¾ÈÀü¼¾ÅÍ µîÀ» ¿î¿µÇÏ¸ç ´ëÇѹα¹ ´ëÇ¥ »ó±ÞÁ¾ÇÕº´¿øÀ¸·Î¼ÀÇ ¿ªÇÒÀ» Ãæ½ÇÈ÷ ¼öÇàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸Á߽ɺ´¿øÀ¸·Î¼ ±â¼ú »ç¾÷È¿¡¼µµ µÎ°¢À» ³ªÅ¸³»¸ç ¼¿ïÁö¿ª À¯ÀÏÀÇ '°³¹æÇü½ÇÇè½Ç'°ú 'Çõ½ÅÇü ÀÇ»ç°úÇÐÀÚ °øµ¿¿¬±¸»ç¾÷' ÁÖ°ü±â°üÀ¸·Î ¼±Á¤µÇ´Â µî ¹ÙÀÌ¿À¸ÞµðÄà ±â¼ú ¿ª·® °È¿¡µµ ¾ÕÀå¼°í ÀÖ½À´Ï´Ù.
¼¿ïƯº°½Ã ±¸·Î±¸ ±¸·Îµ¿·Î 148